Adoption of Biosimilars in the United States and Europe

Bruce A. Feinberg, DO; Hope S. Rugo, MD; Brandon Shank, PharmD, MPH, BCOP; and Marcus H. Snow, MD, consider the adoption of granulocyte-colony stimulating factors and explore how dosage and administration considerations may affect their use in practice.
August 23, 2017
View Text Version

Health economics experts. Managed care professionals. Key clinical specialists. This is where the worlds of clinical, regulatory, and economical outcomes for specialized pharmaceutical biotechnology meet: The Center for Biosimilars® is your online resource for emerging technologies, with a focus on improving critical thinking in the field to impact patient outcomes. We’ll discuss the current landscape for advanced health care management—reviewing emerging treatment paradigms, approaches, and considerations—all by authoritative industry voices.

Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747
Copyright © 2006-2020 Intellisphere, LLC. All Rights Reserved.